The formal requirements for priority have become a hot topic at the European Patent Office, driven by their importance in high-profile oppositions to the Broad Institute’s CRISPR/Cas9 patents, as Catherine Coombes of HGF explains.
A disagreement over how pharma patents in Brazil are examined seems to have come to an end, as Breno Souza, Luisa Rezende and Silvia Costa of Clarke Modet & Co Brazil report.
European developments surrounding the patentability of plants and animals have become rather political, but there are ways for patentees to mitigate the effects of political influence over the patenting process, writes Jane Wainwright of Potter Clarkson.
A new law on supplementary protection certificates will be implemented on April 1, with the application, prosecution and maintenance of SPCs taking centre stage. José Manuel González of Clarke, Modet & Co reports.
President Trump’s decision to pull the US out of the Trans-Pacific Partnership trade deal may have particularly pernicious consequences for the pharmaceutical and biotechnology industries, writes Kevin Noonan of McDonnell Boehnen Hulbert & Berghoff.
Anyone drafting patent licence agreements should follow several tips in order to avoid or better prepare for litigation later on, says Jessamyn Berniker of Williams & Connolly.
Several changes have been made to Italy’s regulatory landscape for biosimilars, as Luca Tosoni of Covington & Burling reports.
A combination of patents, SPCs and regulatory exclusivities should be considered carefully in order to maximise the exclusivity available for cell therapies, as Glyn Truscott of Elkington + Fife explains.
Anyone seeking a deal with a life sciences company must understand the value and potential risks of its IP, as Karen Mangasarian and Ryan Murphey of Ropes & Gray explain.
The IP Life Sciences Exchange, an event for senior IP decision-makers from the life sciences sector, will take place on November 15 and 16 in Munich, Germany. LSIPR previews some of the most interesting sessions.